D1 receptor agonist improves sleep–wake parameters in experimental parkinsonism

Aubert, 2005, Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia, Ann. Neurol., 57, 17, 10.1002/ana.20296 Barraud, 2009, Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model, Exp. Neurol., 219, 574, 10.1016/j.expneurol.2009.07.019 Berthet, 2009, Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of l-DOPA-induced dyskinesia, J. Neurosci., 29, 4829, 10.1523/JNEUROSCI.5884-08.2009 Bezard, 1997, A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey, Brain Res., 766, 107, 10.1016/S0006-8993(97)00531-3 Bezard, 2001, Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease, J. Neurosci., 21, 6853, 10.1523/JNEUROSCI.21-17-06853.2001 Bezard, 2013, Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia, Mov. Disord., 28, 1088, 10.1002/mds.25366 Burgess, 2010, Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy, Sleep, 33, 1295, 10.1093/sleep/33.10.1295 Dzirasa, 2006, Dopaminergic control of sleep–wake states, J. Neurosci., 26, 10577, 10.1523/JNEUROSCI.1767-06.2006 Fernagut, 2010, Dopamine transporter binding is unaffected by l-DOPA administration in normal and MPTP-treated monkeys, PLoS One, 5, e14053, 10.1371/journal.pone.0014053 Ghorayeb, 2007, A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France, Mov. Disord., 22, 1567, 10.1002/mds.21541 Gomez-Mancilla, 1993, Effect of adding the D1 agonist CY 208–243 to chronic bromocriptine treatment. I: evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors, Mov. Disord., 8, 144, 10.1002/mds.870080205 Grondin, 1997, Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys, Neurology, 49, 421, 10.1212/WNL.49.2.421 Hill, 2004, Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease, J. Pharmacol. Exp. Ther., 310, 386, 10.1124/jpet.104.066191 Homann, 2002, Sleep attacks in patients taking dopamine agonists: review, BMJ, 324, 1483, 10.1136/bmj.324.7352.1483 Imbert, 2000, Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey, J. Neurosci. Methods, 96, 71, 10.1016/S0165-0270(99)00184-3 Knie, 2011, Excessive daytime sleepiness in patients with Parkinson's disease, CNS Drugs, 25, 203, 10.2165/11539720-000000000-00000 Laloux, 2008, Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice, J. Sleep Res., 17, 101, 10.1111/j.1365-2869.2008.00625.x Lima, 2008, Blockage of dopaminergic D(2) receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation, Behav. Brain Res., 188, 406, 10.1016/j.bbr.2007.11.025 Manconi, 2012, Dissociation of periodic leg movements from arousals in restless legs syndrome, Ann. Neurol., 71, 834, 10.1002/ana.23565 Marti, 2012, Nociceptin/orphanin FQ receptor agonists attenuate l-DOPA-induced dyskinesias, J. Neurosci., 32, 16106, 10.1523/JNEUROSCI.6408-11.2012 Monti, 1989, Effects of the selective dopamine D-2 receptor agonist, quinpirole on sleep and wakefulness in the rat, Eur. J. Pharmacol., 169, 61, 10.1016/0014-2999(89)90817-0 Ondo, 2001, Daytime sleepiness and other sleep disorders in Parkinson's disease, Neurology, 57, 1392, 10.1212/WNL.57.8.1392 Ongini, 1985, Stimulation of dopamine D-1 receptors by SKF 38393 induces EEG desynchronization and behavioral arousal, Life Sci., 37, 2327, 10.1016/0024-3205(85)90025-6 Pappert, 1999, Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease, Mov. Disord., 14, 117, 10.1002/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0 Qu, 2010, Essential role of dopamine D2 receptor in the maintenance of wakefulness, but not in homeostatic regulation of sleep, in mice, J. Neurosci., 30, 4382, 10.1523/JNEUROSCI.4936-09.2010 Rascol, 2001, Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease, Arch. Neurol., 58, 249, 10.1001/archneur.58.2.249 Rechtschaffen, 1968 Tass, 2012, Coordinated reset has sustained aftereffects in Parkinsonian monkeys, Ann. Neurol., 72, 816, 10.1002/ana.23663 Wisor, 2001, Dopaminergic role in stimulant-induced wakefulness, J. Neurosci., 21, 1787, 10.1523/JNEUROSCI.21-05-01787.2001